Jaguar Health, Inc. (JAGX) Stock

Jaguar Health, Inc. is a pharmaceutical company at the forefront of developing prescription medications for both human and animal gastrointestinal disorders, particularly chronic and debilitating diarrhea. The company operates through two primary segments: Human Health and Animal Health.

Within its Human Health division, Jaguar Health markets Mytesi, aimed at providing symptomatic relief for noninfectious diarrhea in adults living with HIV/AIDS undergoing antiretroviral therapy. Additionally, the company is advancing Crofelemer, a versatile compound with potential applications in various indications. These include cancer therapy-related diarrhea, orphan drug uses for infants and children with congenital diarrheal disorders, and supportive care for inflammatory bowel diseases and short bowel syndrome with intestinal failure. Crofelemer also targets diarrhea-predominant irritable bowel syndrome and idiopathic/functional diarrhea.

Jaguar Health's Animal Health segment focuses on developing Canalevia, a plant-based oral drug candidate designed to manage chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in canines. The company is also developing lechlemer, a second-generation anti-secretory agent tailored for treating cholera. Founded in 2013 and headquartered in San Francisco, California, Jaguar Health continues to innovate in gastrointestinal therapeutics for both human and veterinary applications.